Nov. 21, 2023 Price forecast | 2 weeks: -1.29% | 1 month: 1.14% | 3 months: 6.44%


NGM stock forecast

Our latest prediction for Ngm Biopharmaceuticals Inc's stock price was made on the Nov. 21, 2023 when the stock price was at 0.63$.

In the short term (2weeks), NGM's stock price should underperform the market by -1.29%. During that period the price should oscillate between -9.96% and +8.76%.

In the medium term (3months), NGM's stock price should outperform the market by 6.44%. During that period the price should oscillate between -31.06% and +25.29%.

Create a solid portfolio with NGM

Add NGM to your portfolio and optimize it!


About Ngm Biopharmaceuticals Inc

ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work

At the moment the company generates 165M USD in revenues.

On its last earning announcement, the company reported a loss of -1.82$ per share.

The book value per share is 2.88$

Ngm Biopharmaceuticals Inc website


Three months stock forecastNov. 21, 2023


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
165M - -160M - -112M -1.82 - - 82M 2.88 - - -